Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Non-Current Assets (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Non-Current Assets for 5 consecutive years, with $309.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 1.47% to $309.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 14.91% year-over-year, with the annual reading at $309.2 million for FY2025, 1.47% down from the prior year.
  • Non-Current Assets hit $309.2 million in Q4 2025 for Krystal Biotech, down from $314.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $314.4 million in Q3 2025 to a low of $37.2 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $210.9 million across 5 years, with a median of $204.1 million in 2023.
  • Biggest YoY gain for Non-Current Assets was 380.95% in 2022; the steepest drop was 5.08% in 2022.
  • Year by year, Non-Current Assets stood at $184.0 million in 2021, then fell by 5.08% to $174.7 million in 2022, then skyrocketed by 31.93% to $230.4 million in 2023, then skyrocketed by 36.17% to $313.8 million in 2024, then fell by 1.47% to $309.2 million in 2025.
  • Business Quant data shows Non-Current Assets for KRYS at $309.2 million in Q4 2025, $314.4 million in Q3 2025, and $297.0 million in Q2 2025.